WO2013016531A3 - Composés et méthodes de traitement d'une néoplasie ou d'un cancer - Google Patents

Composés et méthodes de traitement d'une néoplasie ou d'un cancer Download PDF

Info

Publication number
WO2013016531A3
WO2013016531A3 PCT/US2012/048334 US2012048334W WO2013016531A3 WO 2013016531 A3 WO2013016531 A3 WO 2013016531A3 US 2012048334 W US2012048334 W US 2012048334W WO 2013016531 A3 WO2013016531 A3 WO 2013016531A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
neoplasia
compounds
methods
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/048334
Other languages
English (en)
Other versions
WO2013016531A2 (fr
Inventor
Richard A. Gibbs
Joel A. BERGMAN
Kalub HAHNE
Christine A. Hrycyna
Liza SHRESTHA
Markus A. Lill
Gregory Wilson
Jaimeen MAJMUDAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of WO2013016531A2 publication Critical patent/WO2013016531A2/fr
Publication of WO2013016531A3 publication Critical patent/WO2013016531A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne une nouvelle méthode de traitement d'une néoplasie, y compris le cancer et d'autres maladies et affections touchant l'homme ou les autres mammifères. L'invention concerne plus particulièrement, dans des aspects préférés, une méthode d'utilisation de nouveaux composés pour le traitement d'une néoplasie, d'une hyperprolifération cellulaire dont le psoriasis, la resténose consécutive à une chirurgie cardiovasculaire, l'hyperplasie, notamment l'hyperplasie rénale, les maladies inflammatoires chroniques, notamment la polyarthrite rhumatoïde et l'arthrose, entre autres.
PCT/US2012/048334 2011-07-26 2012-07-26 Composés et méthodes de traitement d'une néoplasie ou d'un cancer Ceased WO2013016531A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161511698P 2011-07-26 2011-07-26
US61/511,698 2011-07-26

Publications (2)

Publication Number Publication Date
WO2013016531A2 WO2013016531A2 (fr) 2013-01-31
WO2013016531A3 true WO2013016531A3 (fr) 2013-07-25

Family

ID=47601762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048334 Ceased WO2013016531A2 (fr) 2011-07-26 2012-07-26 Composés et méthodes de traitement d'une néoplasie ou d'un cancer

Country Status (1)

Country Link
WO (1) WO2013016531A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (fr) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Composés lipidiques à utiliser dans des produits cosmétiques, en tant que suppléments alimentaires ou en tant que médicaments
EP2147910A1 (fr) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Nouveaux composés lipidiques
KR101783817B1 (ko) 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
SG10201509127YA (en) 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
US11351139B2 (en) 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2016096566A1 (fr) * 2014-12-17 2016-06-23 Dsm Ip Assets B.V. Formation de chromanes fondée sur une réaction intermoléculaire d'alcynes avec du diméthylfurane en présence de complexes d'or (i)
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180611B1 (en) * 1994-10-05 2001-01-30 Darwin Discovery, Ltd. Peptidyl compounds
WO2002074730A1 (fr) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibiteurs de l'integrine $g(a)v$g(b)¿6?
WO2004087064A2 (fr) * 2003-03-26 2004-10-14 Purdue Research Foundation Compositions et methodes utilisees dans le traitement de la neoplasie et du cancer, basees sur des inhibiteurs de l'isoprenylcysteine methyltransferase
WO2009048541A2 (fr) * 2007-10-05 2009-04-16 Purdue Research Foundation Composés et procédés destinés à être utilisés dans le traitement de la néoplasie et du cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180611B1 (en) * 1994-10-05 2001-01-30 Darwin Discovery, Ltd. Peptidyl compounds
WO2002074730A1 (fr) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibiteurs de l'integrine $g(a)v$g(b)¿6?
WO2004087064A2 (fr) * 2003-03-26 2004-10-14 Purdue Research Foundation Compositions et methodes utilisees dans le traitement de la neoplasie et du cancer, basees sur des inhibiteurs de l'isoprenylcysteine methyltransferase
WO2009048541A2 (fr) * 2007-10-05 2009-04-16 Purdue Research Foundation Composés et procédés destinés à être utilisés dans le traitement de la néoplasie et du cancer

Also Published As

Publication number Publication date
WO2013016531A2 (fr) 2013-01-31

Similar Documents

Publication Publication Date Title
WO2011080568A8 (fr) Nouveaux composés de pyrimidine en tant qu'inhibiteurs de mtor et p13k
WO2012118903A3 (fr) Agents liants bispécifiques
MX343561B (es) Compuestos de imidazolpiridazina.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
WO2013056148A3 (fr) Procédés d'utilisation d'antagonistes de scd1
WO2011060066A9 (fr) Procédés de traitement ou de prévention de thrombose de stent
EP2435825B8 (fr) Procédés de traitement de maladies
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
PL2721076T3 (pl) Sposób ciągłego wytwarzania na linii powlekanych polimerowych podłoży lub laminatów
WO2013037943A8 (fr) Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf
EP2536421A4 (fr) Procédé de traitement du psoriasis
EA201400012A1 (ru) Нацеленная на egfr терапия
WO2009048541A3 (fr) Composés et procédés destinés à être utilisés dans le traitement de la néoplasie et du cancer
MX2012014983A (es) Quinolinas como inhibidores pi3k.
IN2014DN00123A (fr)
WO2013142253A3 (fr) Traitement de cancers du pancréas et de cancers associés par des 5-acyl-6,7-dihydrothiéno[3,2-c]pyridines
WO2004087064A3 (fr) Compositions et methodes utilisees dans le traitement de la neoplasie et du cancer, basees sur des inhibiteurs de l'isoprenylcysteine methyltransferase
WO2013074816A3 (fr) Nouveaux inhibiteurs de nox1
GB201318158D0 (en) Compositions,process of preparation of said compositions and method of treating inflammatory diseases
RU2013105308A (ru) Способ малоинвазивного лечения стриктуры уретры
MX2013006118A (es) Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina.
EP2670717A1 (fr) Procédé et installation de traitement d'hygiénisation de boues
WO2012051251A8 (fr) Procédés de traitement de la lambliase
GB201403383D0 (en) Compositions,process of preparation of said compositions and method of treating inflammatory diseases
WO2013013238A3 (fr) Composés, compositions apparentées et procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12818140

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12818140

Country of ref document: EP

Kind code of ref document: A2